Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.67 |
| ▸ | CTSB | P07858 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.48 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603749 | 0.80 | CTSB (1.00) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4096664 | 0.80 | AR (0.59) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4103060 | 0.80 | AR (0.62) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL3598358 | 0.79 | CTSB (0.97) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4109023 | 0.78 | CTSB (0.56) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4096156 | 0.78 | AR (0.56) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4104009 | 0.78 | AR (0.59) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL4099659 | 0.77 | AR (0.52) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL22858551 | 0.77 | CTSB (0.75) | ARCTSBGAAMAPTTNNI3 | |
| SCHEMBL29577374 | 0.77 | CTSB (0.75) | ARCTSBGAAMAPTTNNI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | claimed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | claimed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | SMITHKLINE BEECHMA CORPORATION (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1851204-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SmithKline Beecham Corporation (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091592-A1 | NAPHTHALENE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093464-A1 | Naphthalene Derivatives as Modulators of the Glucocorticoid Receptor | NR3C1, NR3C2, NR5A1 | AR 38/4885CTSB 4693/4885GAA 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.